Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Longeveron Inc. (NASDAQ: LGVN) SEC filings, giving investors a primary source of regulatory information about the clinical stage biotechnology company and its cellular therapy programs. Longeveron files a range of documents with the U.S. Securities and Exchange Commission, including Forms 8-K, registration statements, and other reports that describe its business, capital structure, and material events.
Recent 8-K filings have detailed topics such as public offerings of Class A common stock and warrants, an at-the-market (ATM) offering agreement, financial results for quarterly periods, changes in executive leadership and board composition, and a Nasdaq notice regarding the minimum bid price requirement for continued listing on The Nasdaq Capital Market. These filings also discuss how the company intends to use offering proceeds, including funding clinical and regulatory development of its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B), for indications like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Through registration statements on Form S-1 and related amendments, Longeveron outlines the terms of securities offerings, its status as an emerging growth and smaller reporting company, and risk factors associated with its business and development plans. Investors can also review disclosures about ATM programs and material definitive agreements with placement agents.
On Stock Titan, these LGVN SEC filings are paired with AI-powered summaries that highlight key points, such as financing terms, listing compliance updates, and planned uses of capital. Users can quickly locate quarterly and annual reporting documents, transaction-related filings, and other regulatory disclosures to better understand Longeveron’s operations, funding strategy, and clinical development priorities.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a Form 4 transaction involving company Class A common stock. On 01/02/2026, 10,250 shares were withheld at a price of $0.593 per share, identified with transaction code "F," which the footnotes explain were shares withheld to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award. Following this tax withholding, she beneficially owned 216,564 shares in total, which the disclosure notes includes RSUs that are still subject to future vesting.
Longeveron Inc. officer reports routine tax withholding transaction. General Counsel and Secretary Paul T. Lehr filed a Form 4 for a transaction on 01/02/2026 involving Class A Common Stock of Longeveron Inc. (LGVN).
The filing shows that 6,952 shares were withheld at a price of $0.593 per share to satisfy tax obligations tied to the vesting of a restricted stock unit (RSU) award. Following this tax withholding, Lehr beneficially owned 344,177 shares, which include RSUs that are subject to future vesting. This reflects an administrative equity compensation event rather than an open-market purchase or sale.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported an insider transaction involving Class A Common Stock. On 01/02/2026, 10,250 shares were withheld at $0.593 per share to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award, rather than an open-market sale. Following this tax withholding, she beneficially owned 228,831 shares, which include RSUs subject to future vesting.
Longeveron Inc. Chief Executive Officer James Nathaniel Powell reported a routine tax-related transaction in the company’s Class A common stock. On 01/02/2026, 2,464 shares were withheld at a price of $0.593 per share to satisfy tax obligations arising from the vesting of a restricted stock unit (RSU) award.
After this withholding, Powell beneficially owned 125,593 shares of Longeveron Class A common stock on a direct basis, which includes RSUs that remain subject to future vesting.
Longeveron Inc. (LGVN) reported that two directors, Khoso Baluch and Neha Motwani, resigned from the Board of Directors, effective immediately on November 7, 2025.
The company stated the resignations were not due to any disagreement regarding its operations, policies, practices, management, or Board. The report was signed by Interim CEO Than Powell.
Longeveron Inc. furnished an 8‑K announcing it issued a press release with financial and operating results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1. The Company states the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
Longeveron Inc. reported Q3 2025 results marked by much lower revenue and a wider loss as the company advances its lead cell therapy program. Total revenue was $137k for the quarter, down from $773k a year ago, reflecting a sharp decline in contract manufacturing activity. Net loss was $7.221M versus $4.419M in Q3 2024.
Cash and cash equivalents were $9.244M as of September 30, 2025. Management states this should fund operations late into Q1 2026 based on the current plan, and it has an ATM facility up to $10.7M in aggregate market value. The filing notes substantial doubt about the company’s ability to continue as a going concern without additional financing.
For the nine months ended September 30, 2025, revenue was $834k (vs. $1.789M in 2024) and net loss was $17.260M (vs. $11.892M). Operating expenses rose, with R&D at $9.321M and G&A at $9.113M. The company is prioritizing its HLHS program and anticipates a potential BLA filing in 2027 if the current ELPIS II trial is successful. As of October 31, 2025, shares outstanding were 19,848,876 Class A and 1,484,005 Class B.
Longeveron Inc. (LGVN)34,000 shares of Class A common stock on 10/01/2025, recorded at a $0 price, as part of a time-based vesting RSU award.
Following the transaction, the reporting person beneficially owned 34,000 shares, held directly. The filing notes the holdings include RSUs subject to future vesting.
Longeveron (LGVN): A reporting person serving as a director filed an initial Form 3. The filing states no securities are beneficially owned, with Table I showing Class A Common Stock: 0 and no derivative securities listed. The date of the event requiring the statement is 10/01/2025. The submission includes a Power of Attorney, with the form signed by an attorney-in-fact.
Nataliya Agafonova, Chief Medical Officer of Longeveron Inc. (LGVN), reported a transaction dated 10/01/2025 on Form 4 showing a sale of 11,883 shares of Class A common stock at a price of $0.7424 per share.
After the reported disposition, the filing shows Agafonova beneficially owns 226,814 shares, which the filer states includes restricted stock units (RSUs) subject to future vesting. The filing also explains that 11,883 shares were withheld to satisfy tax obligations arising from the vesting of an RSU award.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
